Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 6/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18307179 | 0.80 | KMT2A (0.51) | MAP3K12PIK3CAMTOR | |
| SCHEMBL20456804 | 0.80 | KMT2A (0.51) | MAP3K12PIK3CAMTOR | |
| SCHEMBL29739441 | 0.80 | GRIN2D (0.44) | MAP3K12PIK3CAMAP3K7PRMT5FPR1 | |
| SCHEMBL20469192 | 0.80 | PDE10A (0.44) | MAP3K12PIK3CAMAP3K7PRMT5FPR1 | |
| SCHEMBL13187431 | 0.77 | KCNH2 (0.36) | — | |
| SCHEMBL20468889 | 0.77 | CHRNB2 (0.51) | — | |
| SCHEMBL20469184 | 0.76 | MAP3K12 (0.36) | MAP3K12PIK3CAMAP3K7PRMT5FPR1 | |
| Hydrochloric Acid SCHEMBL20491840 | 0.75 | CHRNB2 (0.50) | — | |
| SCHEMBL17560141 | 0.75 | HRH3 (0.45) | FPR1FPR2MTOR | |
| SCHEMBL24018500 | 0.74 | MAP3K12 (0.43) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12084455-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-3909949-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909949-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3577110-B1 | 8-OXETAN-3-YL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL SUBSTITUTED COMPOUNDS AS HIV INHIBITORS | GILEAD SCIENCES INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
| US-10752636-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | HASPIN, NFATC1, NHERF1 | MAP3K12 405/4885PIK3CA 569/4885MAP3K7 145/4885 |
| US-12084455-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | MAP3K12 1018/4885PIK3CA 1666/4885MAP3K7 448/4885 |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
| US-10294234-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | MAP3K12 168/4885PIK3CA 682/4885MAP3K7 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.